Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1-benzoyl-3-pyrazin-2-yl-thiourea is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

31437-04-4

Post Buying Request

31437-04-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

31437-04-4 Usage

Molecular Weight

314.38 g/mol

Appearance

White crystalline solid

Solubility

Slightly soluble in water, soluble in organic solvents like DMSO

Melting Point

192-196°C

+ Benzoyl group (C6H5CO-)

contributes to the compound's aromaticity and potential binding affinity to target proteins.

+ Pyrazinyl group (C4H4N2-)

provides a heterocyclic ring system that may contribute to the compound's biological activity.

+ Thiourea group (NH2CSNH2-)

known for its ability to form hydrogen bonds and coordinate with metal ions, which may contribute to the compound's pharmacological properties.

+ Antitumor potential

The compound has been studied for its ability to inhibit the growth of cancer cells.

+ Antimicrobial properties

1-benzoyl-3-pyrazin-2-yl-thiourea has shown activity against certain bacteria and fungi.

Therapeutic Applications

The compound is being researched for its potential use in the treatment of various diseases, including cancer and infectious diseases.

Pharmaceutical Industry Interest

The versatile chemical structure of 1-benzoyl-3-pyrazin-2-yl-thiourea makes it a promising lead compound for the development of new drugs.

Check Digit Verification of cas no

The CAS Registry Mumber 31437-04-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,1,4,3 and 7 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 31437-04:
(7*3)+(6*1)+(5*4)+(4*3)+(3*7)+(2*0)+(1*4)=84
84 % 10 = 4
So 31437-04-4 is a valid CAS Registry Number.

31437-04-4Relevant articles and documents

The synthesis of 2-amino-4(3H)-quinazolinones and related heterocycles via a mild electrocyclization of aryl guanidines

Sales, Zachary S.,Mani, Neelakandha S.,Allison, Brett D.

supporting information, p. 1623 - 1626 (2018/03/29)

A new method for the preparation of 2-amino-4(3H)-quinazolinones and similar fused heterocycles is described. Simply warming a mixture of an aryl guanidine and carbonyl diimidazole in acetonitrile results in formation of a putative N-amidinoisocyanate intermediate which undergoes a 6π-electron electrocyclic reaction with the aryl ring to generate the quinazolinone ring system. The mild conditions are compatible with a variety of functional groups, and the reaction is shown to be successful on multigram scale.

Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors

Das, Jagabandhu,Furch, Joseph A.,Liu, Chunjian,Moquin, Robert V.,Lin, James,Spergel, Steven H.,McIntyre, Kim W.,Shuster, David J.,O'Day, Kathleen D.,Penhallow, Becky,Hung, Chen-Yi,Doweyko, Arthur M.,Kamath, Amrita,Zhang, Hongjian,Marathe, Punit,Kanner, Steven B.,Lin, Tai-An,Dodd, John H.,Barrish, Joel C.,Wityak, John

, p. 3706 - 3712 (2007/10/03)

A series of structurally novel aminothiazole based small molecule inhibitors of Itk were prepared to elucidate their structure-activity relationships (SARs), selectivity, and cell activity in inhibiting IL-2 secretion in a Jurkat T-cell assay. Compound 3 is identified as a potent and selective Itk inhibitor which inhibits anti-TCR antibody induced IL-2 production in mice in vivo and was previously reported to reduce lung inflammation in a mouse model of ovalbumin induced allergy/asthma.

THIAZOLE DERIVATIVES AND USE THEREOF

-

Page/Page column 50-51, (2010/11/25)

The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential

Press, Neil J.,Taylor, Roger J.,Fullerton, Joseph D.,Tranter, Pamela,McCarthy, Clive,Keller, Thomas H.,Brown, Lyndon,Cheung, Robert,Christie, Julie,Haberthuer, Sandra,Hatto, Julia D.I.,Keenan, Mark,Mercer, Mark K.,Press, Nicola E.,Sahri, Helene,Tuffnell, Andrew R.,Tweed, Morris,Fozard, John R.

, p. 3081 - 3085 (2007/10/03)

The synthesis and SAR of 5-heterocycle-substituted aminothiazole adenosine receptor antagonists is described. Several compounds show high affinity and selectivity for the A2B and A3 receptors. One compound (5f) shows good ADME properties in the rat and as such may be an important new compound in testing the current hypotheses proposing a therapeutic role for a dual A2B/A3 antagonist in allergic diseases.

Pyrimidinone antibiotics - Heterocyclic analogues with improved antibacterial spectrum

Brands, Michael,Grande, Yolanda Cancho,Endermann, Rainer,Gahlmann, Reinhold,Krueger, Jochen,Raddatz, Siegfried

, p. 2641 - 2645 (2007/10/03)

We report the synthesis and pharmacological evaluation of new derivatives of the natural dipeptide antibiotic TAN 1057 A,B containing heterocycles either in the β-amino acid side chain or as mimics of the urea function. In the course of this program, we identified novel analogues that display activity towards a broader panel of Gram-positive bacteriae.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 31437-04-4